Blue Earth highlights new Axumin research

2021 01 16 00 14 5464 Prostate Cancer 400

Bracco molecular imaging subsidiary Blue Earth Diagnostics is directing attention to new research that found PET/CT imaging with its Axumin (fluciclovine F-18) PET radiopharmaceutical had a significant impact on management of patients with recurrent prostate cancer.

In a secondary analysis of the LOCATE and FALCON prospective clinical trials, researchers from the Washington University School of Medicine reported that Axumin PET/CT detected lesions in 85 (58%) of the 146 patients who had received a prescan plan for androgen deprivation therapy, according to Blue Earth. Of the 146, 93 (64%) had a change in their management plan following the exam.

Androgen deprivation therapy was avoided or delayed in 55 (59%) of the 93 patients whose management plan had changed. In addition, only 15 (25%) of the 60 patients originally planned for androgen deprivation therapy monotherapy were still due to receive that treatment plan after Axumin PET/CT imaging, according to Blue Earth.

The results were presented on September 23 at the Global Summit on Precision Diagnosis and Treatment of Prostate Cancer.

Page 1 of 597
Next Page